Bayer Publishes New Late-Breaking Data from Phase 3 Arasens Trial

(PLX AI) – Bayer says Darolutamide plus androgen deprivation therapy and docetaxel demonstrates consistent overall survival benefits across various patient segments in metastatic hormone-sensitive prostate cancer.New subgroup analysis from Phase III …